The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review-Reference-Cited by-同舟云学术

The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review

Published:2017-12-31 Issue:1 Volume:19 Page:107
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Haque Inamul,Subramanian Arvind,Huang Chao,Godwin Andrew,Van Veldhuizen Peter,Banerjee Snigdha,Banerjee Sushanta

Funder

Department of Veterans Affairs

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/19/1/107/pdf

Reference170 articles.

1. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

2. The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma

3. Paraneoplastic Cough and Renal Cell Carcinoma

4. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network

5. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural compounds targeting YAP/TAZ axis in cancer: Current state of art and challenges;Pharmacological Research;2024-05

2. The role of natural products versus miRNA in renal cell carcinoma: implications for disease mechanisms and diagnostic markers;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-05-01

3. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology;The Lancet Oncology;2024-05

4. Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises;Expert Opinion on Drug Delivery;2024-02

5. Kidney Cancer Integrative Oncology: Possible Options for Care;Current Oncology Reports;2023-07-19